%PDF-1.4
%
1 0 obj
<>stream
application/pdf
10.1080/14656566.2020.1745185
en
Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease
Sabina Antonela Antoniu
Ruxandra Rajnoveanu
Ruxandra Ulmeanu
Florin Mihaltan
Mihaela Grigore
Taylor & Francis
Expert Opinion on Pharmacotherapy, 2020. doi:10.1080/14656566.2020.1745185
Chronic obstructive pulmonary disease
inhaled therapies
long-acting antimuscarinic
nebulization
revefenacin
tiotropium
Journal
Expert Opinion on Pharmacotherapy
© 2020 Informa UK Limited, trading as Taylor & Francis Group
1465-6566
1744-7666
21
9
997
1004
10.1080/14656566.2020.1745185
https://doi.org/10.1080/14656566.2020.1745185
VoR
2020-06-01T17:00:04+05:30
Arbortext Advanced Print Publisher 11.0.3433/W Unicode
2021-01-11T09:52:42-08:00
2021-01-11T09:52:42-08:00
Chronic obstructive pulmonary disease; inhaled therapies; long-acting antimuscarinic; nebulization; revefenacin; tiotropium
iText 4.2.0 by 1T3XT
uuid:8c4ecc2f-f3a9-44fb-8ab5-ec0bff664443
uuid:ce423c5f-8c01-42cd-9898-99011c3f7b29
2020-04-01truewww.tandfonline.com10.1080/14656566.2020.1745185www.tandfonline.comtrue2020-04-0110.1080/14656566.2020.1745185
endstream
endobj
4 0 obj
<>stream
xˎ$5_ k'<$4RO?Fp-~;TuMeJO4@p/χO2
&hc] SӇ3Zb)K^}(@6Oݷ NӃ*iJ3H}ճzu Gu^>n?O7x
0p8]C|xo~ТbEᖄ@fؚKL \B'"=*ymJx[S5x..Q+h=
݂\v2L66:6UAO
dN9[?χ?`!(aww ϯƙOtOlNg``]ZY3_kNC,>}5Z|)SA(ҶelsAʍm̋&195f&LbÁQm`\u
W5gjW[ޜ.@Rސx(E"F/K4a#.Y&suȍmD:6v*kGԆ4 :'I ëƘr^a$w2Z sk@,fLq!&7a!&,җHi7lS^~l - ĸ[ƵaRʐlL;m]&b~4[fw7:rd~2/s12TA(0N
Hĥ*
dQVDcZ͜oMVl?䀝0]s"iWFpf!iJ$`9M:l4Lek58#;c.=K [=Dݷ